These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 25449036)

  • 21. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
    J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model.
    Lee HJ; Jeong KH; Kim YG; Moon JY; Lee SH; Ihm CG; Sung JY; Lee TW
    Am J Nephrol; 2014; 40(1):56-63. PubMed ID: 25034030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reducing effect of mangiferin on serum uric acid levels in mice.
    Niu Y; Lu W; Gao L; Lin H; Liu X; Li L
    Pharm Biol; 2012 Sep; 50(9):1177-82. PubMed ID: 22881143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
    Schumacher HR
    Expert Opin Investig Drugs; 2005 Jul; 14(7):893-903. PubMed ID: 16022578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Administration of procyanidins from grape seeds reduces serum uric acid levels and decreases hepatic xanthine dehydrogenase/oxidase activities in oxonate-treated mice.
    Wang Y; Zhu JX; Kong LD; Yang C; Cheng CH; Zhang X
    Basic Clin Pharmacol Toxicol; 2004 May; 94(5):232-7. PubMed ID: 15125693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Febuxostat improves the local and remote organ changes induced by intestinal ischemia/reperfusion in rats.
    Shafik AN
    Dig Dis Sci; 2013 Mar; 58(3):650-9. PubMed ID: 23010742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lithospermic acid as a novel xanthine oxidase inhibitor has anti-inflammatory and hypouricemic effects in rats.
    Liu X; Chen R; Shang Y; Jiao B; Huang C
    Chem Biol Interact; 2008 Nov; 176(2-3):137-42. PubMed ID: 18694741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Febuxostat--treatment for hyperuricemia and gout?
    Moreland LW
    N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
    [No Abstract]   [Full Text] [Related]  

  • 29. The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout.
    Steinberg AS; Vince BD; Choi YJ; Martin RL; McWherter CA; Boudes PF
    J Rheumatol; 2017 Mar; 44(3):374-379. PubMed ID: 27980008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Xanthine oxidoreductase and its inhibitors: relevance for gout.
    Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
    Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Febuxostat versus allopurinol for gout.
    Gelber AC
    N Engl J Med; 2006 Apr; 354(14):1532-3; author reply 1532-3. PubMed ID: 16602151
    [No Abstract]   [Full Text] [Related]  

  • 32. Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
    Oyama J; Tanaka A; Sato Y; Tomiyama H; Sata M; Ishizu T; Taguchi I; Kuroyanagi T; Teragawa H; Ishizaka N; Kanzaki Y; Ohishi M; Eguchi K; Higashi Y; Yamada H; Maemura K; Ako J; Bando YK; Ueda S; Inoue T; Murohara T; Node K;
    Cardiovasc Diabetol; 2016 Jun; 15():87. PubMed ID: 27317093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LASSBio 596 per os avoids pulmonary and hepatic inflammation induced by microcystin-LR.
    Casquilho NV; Carvalho GM; Alves JL; Machado MN; Soares RM; Azevedo SM; Lima LM; Barreiro EJ; Valença SS; Carvalho AR; Faffe DS; Zin WA
    Toxicon; 2011 Aug; 58(2):195-201. PubMed ID: 21679722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
    Takai M; Yamauchi T; Ookura M; Matsuda Y; Tai K; Kishi S; Yoshida A; Iwasaki H; Nakamura T; Ueda T
    Anticancer Res; 2014 Dec; 34(12):7287-96. PubMed ID: 25503162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones.
    Goldfarb DS; MacDonald PA; Gunawardhana L; Chefo S; McLean L
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1960-7. PubMed ID: 23929928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of pharmacokinetics and uric acid lowering effect between two different strength febuxostat formulations (80 mg vs. 40 mg) in healthy subjects.
    Kim KA; Park JY
    Int J Clin Pharmacol Ther; 2015 Aug; 53(8):667-73. PubMed ID: 25997544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Febuxostat].
    Wittköpper K; Emons J; El-Armouche A
    Dtsch Med Wochenschr; 2011 Jun; 136(23):1270-4. PubMed ID: 21607898
    [No Abstract]   [Full Text] [Related]  

  • 38. Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose.
    Carroll MB; Smith DM; Shaak TL
    Rheumatol Int; 2017 Mar; 37(3):445-453. PubMed ID: 27798726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
    Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urate-lowering therapy for gout: focus on febuxostat.
    Love BL; Barrons R; Veverka A; Snider KM
    Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.